Valneva : CMD confirms guidance for short to medium term
>VLA15: phase III results still expected at end-2025 - Valneva yesterday held a CMD which provided an update on the various developments in the portfolio. For VLA15 (Lyme), it confirmed that the phase III programme is on track with 100% of patients (9,000) having received the first three doses (primary vaccination), which points to results by end-2025. If the results are positive, the group will file an approval application in 2026 for launch in 2027, which will trigg...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.